Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
|Videos|September 22, 2016
Precision Medicine Advances in Breast Cancer
Author(s)Steven Katz, MD
Steven Katz, MD, professor, internal medicine, at the University of Michigan Medical School, discusses the major advances in precision medicine in the field of breast cancer.
Advertisement
Advertisement
Related to this article
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy in HER2-positive breast cancer, based on median PFS of 24.9 vs 16.3 months in HER2CLIMB-05.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206
4
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
5